瑞普生物做LP，参设10亿元并购基金

Core Viewpoint - The article discusses the recent establishment of a merger and acquisition (M&A) fund by Reap Bio, highlighting the growing trend of companies participating in M&A funds as a strategic move to enhance their industry influence and operational synergy [2][3][5]. Group 1: Reap Bio's M&A Fund - On February 12, Reap Bio announced the signing of a partnership agreement to establish the Jiangsu Guotai Haitong Reap M&A Industry Fund, with a total scale of RMB 1 billion, where Reap Bio contributes RMB 295 million, accounting for 29.5% of the total [5][6]. - The fund's investment focus includes sectors related to Reap Bio's core business, such as animal health, synthetic biology, pets, and biomedicine, aiming to support the development of the real economy [5][6]. Group 2: Previous M&A Activities - This is not Reap Bio's first involvement as a limited partner (LP); in 2019, it invested RMB 200 million in the Tianjin Huapu Haihe Biomedicine Industry Fund, focusing on biomedicine and agricultural technology [7]. - In October of the previous year, Reap Bio contributed RMB 154 million to establish the Tianjin Baorui Equity Investment Partnership, which targets the pet industry [7]. Group 3: M&A Fund Market Trends - The article notes a significant increase in the establishment of M&A funds, with 305 listed companies participating in 321 funds in 2025, raising a total of RMB 297.51 billion, compared to 268 companies and 288 funds in 2024 [9]. - The M&A market is experiencing a surge in activity, driven by supportive policies and a growing appetite for industry consolidation, with notable transactions across various sectors [10][11]. Group 4: Future Outlook - The M&A market in China is projected to continue its growth, with a transaction volume exceeding USD 400 billion in 2025, marking a 47% year-on-year increase [11]. - The article emphasizes that the ongoing M&A wave is just beginning, with funds playing a crucial role in optimizing asset allocation and driving industry integration [13].